Trial reportDiabetes care2014
Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release.
Trial report in Diabetes care, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Qatar's Silent Epidemic: A Comprehensive Meta-analysis on the Prevalence of Metabolic Syndrome.Current diabetes reviews · 2025Pooled it
- 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association.Diabetes & metabolism journal · 2024Guideline
- Pooled it
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- Long-term effects of weight-reducing drugs in people with hypertension.The Cochrane database of systematic reviews · 2021Pooled it
- Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials.JAMA internal medicine · 2017Pooled it
- Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.The Journal of clinical endocrinology and metabolism · 2021Trial
- Impact of a comprehensive digital health programme on HbADiabetologia · 2020Trial
- International consensus on adolescent metabolic health: prevention of obesity and type 2 diabetes.Diabetology & metabolic syndrome · 2026Review
- A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity.Healthcare (Basel, Switzerland) · 2026Review
- Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity.BMJ open diabetes research & care · 2026Review
- A Narrative Review of Weight Management Strategies: From Lifestyle Interventions to Emerging Pharmacotherapies.Journal of obesity · 2026Review
- 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2026.Diabetes care · 2026Review
- 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026.Diabetes care · 2026Review
- Oral Obesity Medicines in the Era of Cardiovascular-Kidney-Metabolic Syndrome (CKM): Beyond Weight Loss Toward Disease Modification.Drug design, development and therapy · 2026Review
- Impact of yoga on cardiometabolic health in adults with overweight or obesity: A systematic review and meta-analysis of randomized controlled trials.PLOS global public health · 2026Article
- Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Journal of endocrinological investigation · 2025Review
- 2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association.Diabetes & metabolism journal · 2025Article
- Mechanisms and treatment of obesity-related hypertension-Part 2: Treatments.Clinical kidney journal · 2025Review
- 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2025.Diabetes care · 2025Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
OBJECTIVE To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with prediabetes and/or metabolic syndrome (MetS) at baseline. RESEARCH DESIGN AND METHODS Subanalysis of a phase 3, randomized, placebo-controlled, double-blind study of overweight/obese subjects (BMI ≥27 to ≤45 kg/m(2)) with two or more comorbidities. Subjects were randomized to placebo, PHEN 7.5 mg/TPM ER 46 mg (7.5/46), or PHEN 15 mg/TPM ER 92 mg (15/92) plus lifestyle modifications for 108 weeks. Percent weight loss in the intent-to-treat population using multiple imputation (ITT-MI), annualized incidence rate of progression to type 2 diabetes, and changes in glycemia, lipid parameters, blood pressure, and waist circumference were evaluated. RESULTS At baseline, 475 subjects met the criteria for prediabetes and/or MetS. After 108 weeks, subjects with prediabetes and/or MetS in the placebo, 7.5/46, and 15/92 groups experienced mean percent weight loss of 2.5, 10.9, and 12.1%, respectively (ITT-MI; P < 0.0001 vs. placebo), associated with reductions of 70.5 and 78.7% in the annualized incidence rate of type 2 diabetes for those receiving 7.5/46 and 15/92, respectively (ITT, P < 0.05), versus placebo. The ability of PHEN/TPM ER to prevent diabetes was related to degree of weight lost and was accompanied by significant improvements in cardiometabolic parameters. PHEN/TPM ER was well tolerated by this subgroup over 2 years. CONCLUSIONS PHEN/TPM ER plus lifestyle modification produced significant weight loss and markedly reduced progression to type 2 diabetes in overweight/obese patients with prediabetes and/or MetS, accompanied by improvements in multiple cardiometabolic disease risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.